Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trebananib + Paclitaxel in Recurrent Ovarian Cancer
NCT00479817Phase 2Completed
- Sponsor
- Amgen
- Start
- Jul 2007
- Primary completion
- Aug 2009
- Modality
- Peptides, Antibody-Based Therapeutics, Fc-Fusion Proteins
01
Overview
Phase 2, randomised, double-blind trial of trebananib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (3 arms), sponsored by Amgen. Primary endpoint: Progression Free Survival at 2 years. Started Jul 2007; status: completed.
02
Drugs
trebananib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00479817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00479817.